💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Exclusive-WHO says partners can start talks to buy mpox vaccines before its approval

Published 08/23/2024, 07:26 AM
Updated 08/23/2024, 11:16 AM
© Reuters. FILE PHOTO: A medical worker holds a syringe with the mpox vaccine at a vaccination center in Nice, France, July 27, 2022.  REUTERS/Eric Gaillard/File Photo
BAVA
-

By Jennifer Rigby

LONDON (Reuters) -The World Health Organization said on Friday its partners such as Gavi and UNICEF can start buying mpox vaccines before they are approved by the U.N. health agency, to get inoculations to Africa faster as the continent battles an escalating outbreak of the virus. 

Traditionally, organisations like Gavi, which helps lower-income countries buy vaccines, can only start purchasing shots once they have approval from the WHO. But the rules have been relaxed in this instance to get talks moving, as the WHO's approval is due in a few weeks.

Two vaccines, made by Denmark's Bavarian Nordic and Japan's KM Biologics, are already approved by regulators around the world, including the U.S. and Japan, and have been in widespread use for mpox since 2022. Around 1.2 million people have had Bavarian Nordic's vaccine in the U.S. alone. The WHO is expected to grant an emergency licence to the shots in September.

Mpox, a viral infection that spreads through close contact and is usually mild but can kill, was declared a public emergency of international concern by the WHO last week after a new offshoot of the virus spread quickly in Democratic Republic of Congo and beyond.

Earlier this month, the WHO asked vaccine manufacturers to submit information so it could accelerate its approval process, and grant an emergency licence by mid-September. 

However this week, one of the vaccine manufacturers, Bavarian Nordic, said it needed orders immediately from organisations such as Gavi and the WHO to make more shots this year, raising fears that lower-income countries could miss out or be forced to rely on precarious donations from high-income countries, as happened during the COVID-19 pandemic.

Some donated mpox vaccines are due to arrive in Africa next week, the Africa Centres for Disease Control and Prevention has said. The agency has said 10 million doses are needed.  

"While we see the news from WHO as a positive, we are not able to comment on specific negotiations. We will update the market in due time if and when orders materialize," a spokesperson for Bavarian Nordic said.

A spokesperson for Gavi said that getting donated doses to countries, and into vaccination programmes, was the first priority.

© Reuters. FILE PHOTO: A medical worker holds a syringe with the mpox vaccine at a vaccination center in Nice, France, July 27, 2022.  REUTERS/Eric Gaillard/File Photo

"When it comes to procuring vaccines directly, since a public health emergency of international concern was announced last week, we have intensified our efforts, with near-daily contact with manufacturers: we are ready to go as soon as we get a clear picture on demand,” the spokesperson said.

KM Biologics did not immediately respond to requests for comment. 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.